Hodgkin's LymphomaNCT01483664
Communication Skills Intervention to Promote Transition Into Survivorship
An observational study of Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma, run by Memorial Sloan Kettering Cancer Center at 9 sites in United States.
Trial summary
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
- How many people
- 314 participants
- Where
- 9 sitesUnited States
- Study dates
- Nov 2011to Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients: Patients from each site will be recruited from their respective lymphoma services. Physicians: Physicians from each site will be recruited from their respective lymphoma services.
Who may be able to join
- Physicians:
- who treat patients with DLBCL and HD as per self report
- Patients of Physicians:
- have a new diagnosis of Hodgkin's or Diffuse Large B-cell Lymphoma as per pathology report or physician assessment in medical record and/or clinical judgment of the treating physician treated with curative intent.
- For part 1 - have scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
- For part 2 (longitudinal phase): - have new scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
- be at least 18 years old
- speak English well enough, in the judgment of the consenting professional, to be able to understand all aspects of the study, provide informed consent, and be able to complete all study measures.
Who cannot join
- Physicians:
- who do not have adequate patients in their clinical practice to meet the 8 patient enrollment requirement for patients with either DLBCL or HD as per self report
- Patients of Physicians:
- show evidence of cognitive impairment severe enough to preclude giving permission to the study staff, or completing the survey instruments of the study.
- as per physician judgment, patient's prognosis and/or co-morbidities make them inappropriate for participation in a survivorship study.
- For Part 2 ONLY (longitudinal phase):
- those who consented to part 1, consult recording, of the study.
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
United States9 sites
Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, 07920
Maimonides Medical Center
Brooklyn, New York, 11220
Memorial Sloan Kettering Cancer Center at Commack
Commack, New York, 11725
Md Anderson Cancer Center
Houston, Texas, 77030
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Memorial Sloan Kettering Cancer Center at Mercy
Rockville Centre, New York, 11570
Memorial Sloan Kettering Cancer Center at Phelps
Sleepy Hollow, New York, 10591
Tampa General Hospital
Tampa, Florida, 33606
Moffitt Cancer Center
Tampa, Florida, 33612
About this study
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
- Conditions
- Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
- Keywords
- patient outcomes, Survivorship, Communication Skills, Communication strategies, Physicians communication, 11-180
- Medical subject headings
- Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| initial survivorship planning consultation | The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site. | |
| initial wellness rehabilitation consultation | The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site. |
What is being measured
The primary outcome is the main question the study is designed to answer.
impact on patient outcomes of targeted physician communication skills training
Measured: 3 years
Secondary outcomes (2)
impact of a targeted CST intervention on the physicians
use of strategies, tasks and skills about transitioning lymphoma patients from the end of primary treatment to survivorship.
Measured: 3 years
describe communication during doctor-patient visits during the patients' first three years of survivorship
(MSKCC and MD Anderson baseline data only) The study team will look for qualitative themes to better understand the content of these conversations and the need for survivorship care planning. Half of these recordings were with MSKCC patients and physicians and half were with MD Anderson patients and physicians.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2011 (estimated)
- Study startNov 2011
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hodgkin's LymphomaStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 314 participants (actual)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- M.D. Anderson Cancer Center, Maimonides Medical Center, H. Lee Moffitt Cancer Center and Research Institute, Rutgers University, Tampa General Hospital, University of California, Los Angeles, National Cancer Institute (NCI), Monash University, Weill Cornell Medical College in Qatar, New York Presbyterian Brooklyn Methodist Hospital, San Francisco State University
- Responsible party
- Sponsor
- Investigators
- Patricia Parker, PhD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01483664
- Sponsor's protocol ID
- 11-180
- Status last verified
- Jan 2026
- First submitted
- 29 Nov 2011
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Parker PA, Banerjee SC, Matasar MJ, Bylund CL, Franco K, Li Y, Levin TT, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane DW. Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma. BMJ Open. 2016 Jun 28;6(6):e011581. doi: 10.1136/bmjopen-2016-011581.
PubMed 27354079
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Communication Skills Intervention to Promote Transition Into Survivorship
- ClinicalTrials.gov ID
- NCT01483664
- Acronym / sponsor ID
- 11-180
- Conditions
- Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
- Keywords
- patient outcomes, Survivorship, Communication Skills, Communication strategies, Physicians communication, 11-180
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 314 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Collaborators
- M.D. Anderson Cancer Center, Maimonides Medical Center, H. Lee Moffitt Cancer Center and Research Institute, Rutgers University, Tampa General Hospital, University of California, Los Angeles, National Cancer Institute (NCI), Monash University, Weill Cornell Medical College in Qatar, New York Presbyterian Brooklyn Methodist Hospital, San Francisco State University
- Study start
- Nov 2011
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 1 Dec 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| initial survivorship planning consultation | – | –The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site. |
| initial wellness rehabilitation consultation | – | –The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients: Patients from each site will be recruited from their respective lymphoma services. Physicians: Physicians from each site will be recruited from their respective lymphoma services.
Key inclusion criteria (8 listed)
- who treat patients with DLBCL and HD as per self report
- have a new diagnosis of Hodgkin's or Diffuse Large B-cell Lymphoma as per pathology report or physician assessment in medical record and/or clinical judgment of the treating physician treated with curative intent.
- For part 1 - have scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
- For part 2 (longitudinal phase): - have new scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
- be at least 18 years old
Key exclusion criteria (7 listed)
- who do not have adequate patients in their clinical practice to meet the 8 patient enrollment requirement for patients with either DLBCL or HD as per self report
- show evidence of cognitive impairment severe enough to preclude giving permission to the study staff, or completing the survey instruments of the study.
- as per physician judgment, patient's prognosis and/or co-morbidities make them inappropriate for participation in a survivorship study.
- those who consented to part 1, consult recording, of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
impact on patient outcomes of targeted physician communication skills training
Time frame: 3 years
2 secondary outcomes
impact of a targeted CST intervention on the physicians
Time frame: 3 years
describe communication during doctor-patient visits during the patients' first three years of survivorship
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Derived from this study: PubMed 27354079Parker PA, Banerjee SC, Matasar MJ, Bylund CL, Franco K, Li Y, Levin TT, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane DW. Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma. BMJ Open. 2016 Jun 28;6(6):e011581. doi: 10.1136/bmjopen-2016-011581.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Hodgkin's Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Active, not recruitingPhase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
B Cell ALL, B-Cell Lymphoma
Active, not recruitingPhase 1
A Rollover Study of CC-122
Non-Hodgkin Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patricia Parker, PhD principal investigator
Memorial Sloan Kettering Cancer Center
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma, run by Memorial Sloan Kettering Cancer Center at 9 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
impact on patient outcomes of targeted physician communication skills training (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01483664, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.